197 related articles for article (PubMed ID: 32248338)
1. Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen B; Wu Z; Wang Q; Li W; Cheng D
Invest New Drugs; 2020 Oct; 38(5):1627-1632. PubMed ID: 32248338
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia.
Ng IK; Ruparel M; Chan EH; Khoo KL
J R Coll Physicians Edinb; 2024 Mar; 54(1):44-47. PubMed ID: 38486345
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia.
Alqattan Y; Ali S; Almohammad R; Kayali N; Alhuraiji A
Gulf J Oncolog; 2022 Sep; 1(40):74-77. PubMed ID: 36448074
[TBL] [Abstract][Full Text] [Related]
4. Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan".
Sasaki H; Kimizuka Y; Ogata H; Okada Y; Ota S; Sano T; Watanabe C; Maki Y; Yamamoto T; Tagami Y; Miyata J; Hayashi N; Fujikura Y; Kawana A
Intern Med; 2019 Nov; 58(21):3139-3141. PubMed ID: 31292394
[TBL] [Abstract][Full Text] [Related]
5. [Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Yang L; Lu N; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1348-1353. PubMed ID: 27784355
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.
Kelly RL; Bae JY; D'Annunzio S; Montanari F
Am J Case Rep; 2022 Nov; 23():e938319. PubMed ID: 36444127
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Hickman K; Diaz E; Graham R; Adams R; Ngwube A
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e665-e667. PubMed ID: 31688632
[TBL] [Abstract][Full Text] [Related]
8. Chylothorax: complication attributed to dasatinib use.
Al-Abcha A; Iftikhar MH; Abu Rous F; Laird-Fick H
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31848139
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.
Liu Q; Fu J; Zhang A
Transl Cancer Res; 2023 Jan; 12(1):194-200. PubMed ID: 36760377
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
11. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
12. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Kaiafa G; Kakaletsis N; Savopoulos C; Perifanis V; Giannouli A; Papadopoulos N; Zisekas S; Hatzitolios AI
J Clin Pharm Ther; 2014 Feb; 39(1):102-5. PubMed ID: 24188312
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.
Paul T; Ellahie AY; Almohtasib YS; Sinha U; El Omri H
EJHaem; 2021 Aug; 2(3):545-550. PubMed ID: 35844702
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.
Hsu CC; Hsu JF; Wu KL
Respirol Case Rep; 2021 Jun; 9(6):e00753. PubMed ID: 33976882
[TBL] [Abstract][Full Text] [Related]
16. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
17. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
18. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
19. Intercostal Herniation of Pleural Fluid.
Newman TA; Brady AK; Shriki JE; Takasugi JE; Adamson R
Am J Respir Crit Care Med; 2020 Jan; 201(2):e5. PubMed ID: 31433948
[No Abstract] [Full Text] [Related]
20. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
